Alefacept (Amevive) for treatment of psoriasis. Med Lett Drugs Ther. 2003 Apr;45(1154):31-32. PMID: 12717339
Ashcroft DM, Li Wan Po A, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000 Apr;320(7240):963-967. http://www.ncbi.nlm.nih.gov/pubmed/?term=10753146. PMID: 10753146
Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther. 2003 Dec;45(1171):97-98. PMID: 14657802
Cohen SN, Baron SE, Archer CB; British Association of Dermatologists and Royal College of General Practitioners. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012 May;37(Suppl 1):13-18. doi: 10.1111/j.1365-2230.2012.04337.x. PMID: 22486764
Drew GS. Psoriasis. Prim Care. 2000 Jun;27(2):385-406. http://www.ncbi.nlm.nih.gov/pubmed/?term=Drew+GS%09Psoriasis. PMID: 10815050
Kollner K, Wimmershoff MB, Hintz C, et al. Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311- nm narrowband ultraviolet B in the treatment of psoriasis. Br J Dermatol. 2005 Apr;152(4):750-754. http://www.ncbi.nlm.nih.gov/pubmed/?term=15840108. PMID: 15840108
Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol. 2004 Apr;50(4):613-622. http://www.ncbi.nlm.nih.gov/pubmed/?term=Koo+J%2C+Lee+E%2C+Lee+CS%2C+et+al%09+Psoriasis. PMID: 15034513
Ladizinski B, Lee KC, Wilmer E, et al. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013 Jun;26(6):271-284. http://www.ncbi.nlm.nih.gov/pubmed/?term=23669329. PMID: 23669329
Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001 Oct;45(4):487-498. http://www.ncbi.nlm.nih.gov/pubmed/?term=Lebwohl+M%2C+Ali+S%09%22Treatment+of+psoriasis.+Part+1.+Topical+therapy+and+phototherapy%22. PMID: 11568737
Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004 Mar;50(3):416-430. http://www.ncbi.nlm.nih.gov/pubmed/14988684. PMID: 14988684
Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001 Nov;45(5):649-661. http://www.ncbi.nlm.nih.gov/pubmed/?term=11606913. PMID: 11606913
Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician. 2006 Feb;73(4):636-644. https://www.aafp.org. PMID: 16506705
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr;60(4):643-659. doi: 10.1016/j.jaad.2008.12.032. PMID: 19217694
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep;61(3):451-485. http://www.ncbi.nlm.nih.gov/pubmed/?term=19493586. PMID: 19493586
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826-850. http://www.ncbi.nlm.nih.gov/pubmed/?term=18423260. PMID: 18423260
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-174. http://www.ncbi.nlm.nih.gov/pubmed/?term=21306785. PMID: 21306785
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan;62(1):114-135. doi: 10.1016/j.jaad.2009.08.026. PMID: 19811850
Mudigonda T, Dabade TS, West CE, et al. Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy. Cutis. 2012 Sep;90(3):149-154. http://www.ncbi.nlm.nih.gov/pubmed/?term=23094316. PMID: 23094316
Ortonne JP, Humbert P, Nicolas JP, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 mcg g -1 ointment and calcipotriol 50 mcg g -1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003 Feb;148(2):326-333. http://www.ncbi.nlm.nih.gov/pubmed/?term=Ortonne++JP%2C+Humbert++P%2C++Nicolas++JP%2C+et++al%09%22Intra-individual+comparison+of+the+cutaneous+safety+and+efficacy+of+calcitriol+3+mcg+g+-1++ointment+and+calcipotriol+50+mcg+g+-1+ointment+on+chronic++plaque+. PMID: 12588387
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005 Sep;153(3):486-497. http://www.ncbi.nlm.nih.gov/pubmed/?term=16120132. PMID: 16120132
Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician. 2000 Feb;61(3):725-733, 736. https://www.aafp.org. PMID: 10695585
Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010 Sep;86(3 Suppl):5-31. PMID: 21049712
Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol. 2002 Nov;47(5):701-708. http://www.ncbi.nlm.nih.gov/pubmed/?term=12399761. PMID: 12399761
Habif TP. Psoriasis and other papulosquamous diseases. In: Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 5th ed. Pennsylvania: Mosby, Elsevier; 2010.
Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. Toronto Dermatology Centre. http://www.torontodermatologycentre.com. Aug 2011. Accessed 19 Jul 2013.
National Institute for Health and Clinical Excellence (NICE). Adalimumab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jun 2008.
Ministry of Malaysia, Dermatological Society of Malaysia, Academy of Medicine Malaysia. Management of psoriasis. Second edition. Academy of Medicine Malaysia. https://www.acadmed.org.my. 2024.
Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of psoriasis and psoriatic arthritis in adults. SIGN. http://www.sign.ac.uk. 2010.
National Institute for Health and Clinical Excellence (NICE). Etanercept and efalizumab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jul 2006.
British Association of Dermatologists. Psoriasis guideline. British Association of Dermatologists. http://www.bad.org.uk. 2006. Accessed 07 Nov 2006.
National Institute for Health and Clinical Excellence (NICE). Infliximab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jan 2008.
National Institute for Health and Clinical Excellence (NICE). Psoriasis: the assessment and management of psoriasis. NICE. http://www.nice.org.uk. Oct 2012.
National Psoriasis Foundation. Psoriasis severity. National Psoriasis Foundation. http://www.psoriasis.org. 2013. Accessed 19 Jul 2013.
National Institute for Health and Clinical Excellence (NICE). Ustekinumab for the treatment of adults with moderate to severe psoriasis. NICE. http://www.nice.org.uk. Sep 2009.
Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab): highlights of prescribing information. Novartis. http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdf. Jan 2015. Accessed 30 Jan 2015.
U.S. Food & Drug Administration. FDA approves new psoriasis drug Cosentyx. US FDA. http://www.fda.gov/. 21 Jan 2015. Accessed 30 Jan 2015.
Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris - update 2015 - short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-2294. doi: 10.1111/jdv.13354. Accessed 06 Apr 2016. PMID: 26481193
Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665. Accessed 29 Jun 2017. PMID: 28513835
American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-174. doi: 10.1016/j.jaad.2010.11.055. PMID: 21306785
Nast A, Spuls PI, van der Kraaij G, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris – update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963. doi: 10.1111/jdv.14454. Accessed 28 May 2018. PMID: 28895202
National Institute for Health and Care Excellence (NICE). Apremilast for treating moderate to severe plaque of psoriasis. NICE. http://www.nice.org.uk/. Nov 2016. Accessed 28 May 2018.
Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013 May;87(9):626-633. https://www.aafp.org/. Accessed 28 May 2018. PMID: 23668525
Nast A, Boehncke WH, Mrowietz U, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012 Mar;10(Suppl 2):S1-S95. doi: 10.1111/j.1610-0387.2012.07919.x. PMID: 22386073
Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Accessed 04 Apr 2019. PMID: 30773097
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Accessed 04 April 2019. PMID: 30772098
National Institute for Health and Care Excellence (NICE). Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE. http://www.nice.org.uk. Sep 2017. Accessed 10 April 2019.
U.S. Food & Drug Administration (US FDA). Biosimilar product information. US FDA. https://www.fda.gov/. 24 Feb 2020. Accessed 28 Feb 2020.
Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Accessed 04 Feb 2020. PMID: 31351884
Smith CH, Yiu ZZ, Bale T, et al; British Association of Dermatologists’ Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. Br J Dermatol. 2020 Oct;183(4):628-637. doi: 10.1111/bjd.19039. Accessed 05 Jun 2020. PMID: 32189327
Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020 Jul:S0190-9622(20)32288-X. doi: 10.1016/j.jaad.2020.07.087. Accessed 09 Dec 2020. PMID: 32738429
Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun;82(6):1445-1486. doi: 10.1016/j.jaad.2020.02.044. Accessed 09 Dec 2020. PMID: 32119894
Dermatologicals. WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index. 14 Dec 2021. Accessed 09 Feb 2022.
Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. doi: 10.1111/jdv.16915. PMID: 33349983
Pai SB, Shetty S. Guidelines for bath PUVA, bathing suit PUVA and soak PUVA. Indian J Dermatol Venereol Leprol. Nov-Dec 2015;81(6):559-567. doi: 10.4103/0378-6323.168336. PMID: 26515832
Verallo-Rowell VM, Katalbas SS, Evangelista MTP, et al. Review update on topical therapy for psoriasis. Curr Derm Rep. 2018;7:24-36. https://doi.org/10.1007/s13671-018-0209-x.
Finnish Medical Society Duodecim. Psoriasis. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2005 May.
U.S. Food & Drug Administration (US FDA). Abrilada highlights of prescribing information. US FDA. https://www.fda.gov/. Nov 2019. Accessed 18 Aug 2022.
Blauvelt A, Ehst BD. Pathophysiology of plaque psoriasis. UpToDate. https://www.uptodate.com. 12 Oct 2021.
Feldman SR. Psoriasis: epidemiology, clinical manifestations, and diagnosis. UpToDate. https://www.uptodate.com. 26 Nov 2024. Accessed 24 Apr 2023.
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017 Sep;140(3):645-653. doi: 10.1016/j.jaci.2017.07.004. PMID: 28887948
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019 Mar;20(6):1475. doi: 10.3390/ijms20061475. PMID: 30909615
World Health Organization (WHO). Global report on psoriasis. WHO. https://www.who.int/. 2016.
Budamakuntla L, Shree-Lakshmi HV, Bansal A, et al. Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India. Psoriasis (Auckl). 2019;9:19-27. doi: 10.2147/PTT.S154073. PMID: 31119094
Feldman SR. Treatment of psoriasis in adults. UpToDate. https://www.uptodate.com. 30 Jun 2023.
Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 Nov;76(11):1890-1896. doi: 10.1136/annrheumdis-2017-211384. PMID: 28814432
Electronic Medicines Compendium (EMC). British Association of Dermatologists patient information leaflet | Certolizumab pegol. EMC. https://www.medicines.org.uk/. 27 Jul 2022.
Gordon KB, Warren RB, Gottlieb AB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021 Apr;184(4):652-662. doi: 10.1111/bjd.19393. PMID: 32652544
Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. . 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Accessed 28 Oct 2024. PMID: 29660421
Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228-233. doi: 10.1136/annrheumdis-2017-212196. PMID: 29030361
Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023 Sep;89(3):486-495. doi: 10.1016/j.jaad.2023.04.063. Accessed 28 Oct 2024. PMID: 37182701
Blauvelt A, Iversen L, McBride S, et al. Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial. SKIN The Journal of Cutaneous Medicine. 2021 Nov;5:s52. doi: s53. 10.25251/skin.5.supp.53.
Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 Feb;397(10273):1182. doi: 10.1016/S0140-6736(21)00669-3. PMID: 33549192
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 Feb;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Accessed 28 Oct 2024. PMID: 33549193
Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021 Jul;385(2):130-141. doi: 10.1056/NEJMoa2102388. Accessed 28 Oct 2024. PMID: 33891379
Blauvelt A, Foley P, Langley R, et al. Bimekizumab 4-year maintenance of responses in week 16 responders with moderate to severe plaque psoriasis: results from the BE BRIGHT open label extension phase 3 trial. Journal of the American Academy of Dermatology. 2024 Sep;91(3):AB23. doi: 10.1016/j.jaad.2024.07.102.
National Health Service (NHS). Clinical protocol: treatment pathway for adults with moderate to severe psoriasis. NHS. https://www.nhs.uk/. Aug 2024.
Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update. Br J Dermatol. 2024 Jan;190(2):270-272. doi: 10.1093/bjd/ljad347. PMID: 37740557
Feldman SR, Lewitt GM. Chronic plaque psoriasis in adults: treatment of disease amenable to topical therapy. UpToDate. https://www.uptodate.com. 16 Jun 2025.
Feldman SR, Soung J. Chronic plaque psoriasis in adults: treatment of disease requiring phototherapy or systemic therapy. UpToDate. https://www.uptodate.com. 15 Oct 2025.
Nast A, Spuls PI, Dressler C, et al. EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris: European Dermatology Forum. European Dermatology Forum. https://www.guidelines.edf.one. Feb 2025.
Ranaweera A. Tildrakizumab. Dermznet. https://dermnetnz.org/. May 2018.
Nast A, Altenburg A, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: treatment recommendations and monitoring. J Dtsch Dermatol Ges. 2026 Jan;24(1):122-137. doi: 10.1111/ddg.16002. PMID: 41531416
Nast A, Altenburg A, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 2: specific clinical and comorbid situations. J Dtsch Dermatol Ges. 2026 Feb;24(2):270-282. doi: 10.1111/ddg.16001. PMID: 41641952
Rizal Medical Center - Technical Working Group. Psoriasis clinical pathway. Philippine Dermatological Society. https://pds.org.ph/. Jun 2022.
